STOCK TITAN

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Record Q3 Revenue, Up 785% Year-over-Year to $2.53 Million and Up 94% From Previous Quarter; Files Form 10-Q for Q3 2026; Total Assets of $133.1 Million Include $100.4 Million Held in Trust by Sponsored SPAC

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

PMGC Holdings (Nasdaq: ELAB) reported record third-quarter 2026 revenue of approximately $2.53 million as all five acquisitions contributed for a full quarter. Revenue rose 785% year over year and 94% sequentially. Gross profit reached approximately $601,000, but gross margin fell to 23.8% from 29.5% sequentially. Net loss narrowed to approximately $2.24 million; operating expenses fell 27% sequentially to approximately $3.08 million.

Total assets were approximately $133.1 million, including $100.4 million in sponsored SPAC NorthStrive Acquisition Corp I's restricted trust, unavailable for PMGC operations. Cash excluding that trust was approximately $13.0 million. NSAI subsequently signed a proposed Nuclea Energy combination based on a $350 million value, subject to adjustments and closing conditions. PMGC also reported preliminary EL-32 animal-study findings, with lean-mass benefits limited to specific measures and doses.

Loading...
Loading translation...
23 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 14 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointQ3 revenue of approximately $2.53 million rose 785% year over year and 94% sequentially.
  • Moderate pointGross profit of approximately $601,000 increased 671% year over year and 56% sequentially.
  • Moderate pointOperating expenses of approximately $3.08 million fell 27% sequentially, although up 35% year over year.
  • Moderate pointNet loss of approximately $2.24 million narrowed 14% year over year and 24% sequentially.
  • Moderate pointAssets excluding restricted trust cash of approximately $32.7 million rose 154% from year-end and 119% year over year.
  • Moderate pointCash excluding the trust of approximately $13.0 million rose 140% from year-end and 69% year over year.
  • Moderate pointPMGC stockholders’ equity of approximately $12.1 million rose 55% from year-end and 43% year over year.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.PAD Group agreement provides two years of aerospace manufacturing work under purchase orders, with automatic one-year renewals.
  • Moderate pointPacific Sun gross margin of 47.0% for nine months compared with 29.1% from acquisition through year-end 2025.
  • Moderate pointRoyalty payment agreement covers acknowledged 2025 royalties of $94,937 and future royalties, in $10,000 monthly installments beginning October 15, 2026. 7.4% of market cap
  • Moderate pointNSAI’s definitive Nuclea agreement values Nuclea at $350 million, subject to closing adjustments.
12 minor points
  • Minor pointLoss attributable to PMGC stockholders of $2,406,301 narrowed 7% year over year and 18% sequentially.
  • Minor pointContinuing-operations net loss of $2,220,853 narrowed 15% year over year and 25% sequentially.
  • Minor pointNine-month revenue of approximately $4.52 million was approximately 7.7 times full-year 2025 revenue.
  • Minor pointManufacturing equipment investment added equipment supporting automated production; PMGC is evaluating further robotics and automation.
  • Minor pointWorldwide exclusive drone payload patent license was executed with the Florida State University Research Foundation.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Four AI-selected compounds increased ANT1 protein expression in human muscle cells; expansion toward lead selection is planned.
  • Minor pointTwo U.S. patent applications cover EL-22 and EL-32 for muscle loss in microgravity.
  • Minor pointCharles River Laboratories statement of work supports the EL-22 and EL-32 programs.
  • Minor pointEL-32 plus semaglutide produced statistically greater absolute lean mass at the highest tested EL-32 dose versus semaglutide alone.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Follow-on EL-32 preclinical study is planned with lower-dose semaglutide and lean-mass and body-composition endpoints.
  • Minor pointOrbit2Orbit common-share subscription was completed by PMGC Capital.
  • Minor point. Forward-looking: it has not happened yet and may not happen.PMGC plans further capacity and automation investment and acquisitions of established, cash-flow-positive businesses.

Negative

  • Major pointApproximately $4.9 million non-cash charge reduced additional paid-in capital to remeasure NSAI public shares to redemption value. 3.8× market cap
  • Major point. Forward-looking: it has not happened yet and may not happen.PMGC’s $1,845,000 debenture subscription commitment would fund a Nuclea subsidiary’s Moltex acquisition. 1.4× market cap
  • Major point. Forward-looking: it has not happened yet and may not happen.NSAI going-concern doubt applies if it does not complete a business combination by August 19, 2027.
  • Moderate pointQ3 gross margin of 23.8% fell 5.7 percentage points sequentially and 3.5 points year over year.
  • Moderate pointCash of $12,981,851 declined from $18,141,758 at June 30, 2026.
  • Moderate pointTotal liabilities of $21,033,639 exceeded $19,827,597 at June 30 and $5,031,111 at year-end 2025.
  • Moderate pointPMGC stockholders’ equity of $12,109,044 declined from $16,736,899 at June 30, 2026.
  • Moderate pointNSAI trust cash of approximately $100.4 million is restricted and unavailable to fund PMGC operations.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Nuclea transaction closing requires shareholder and regulatory approvals, Moltex acquisition completion and at least $3.0 million available NSAI cash.
5 minor points
  • Minor pointAssets excluding restricted trust cash of $32,678,587 declined from $36,564,496 at June 30, 2026.
  • Minor pointPAD Group agreement has no guaranteed minimum purchase volume.
  • Minor pointGPS-denied drone navigation technology held under option requires independent validation, for which Deploy360 was engaged.
  • Minor pointEL-32 combination findings are preliminary and limited to specific measures and doses.
  • Minor pointEL-32 combination showed no consistent additive metabolic benefit; EL-32 alone showed no meaningful improvements.

News Explained

Separately from the proposed NSAI combination, PMGC has agreed to commit $1,845,000 to debentures issued by a Nuclea subsidiary to fund its pending Moltex-asset acquisition; this is a direct PMGC funding commitment connected to Nuclea.

Argus 15 min delay 18 alerts
+3.21% vs previous close $1.63 last price 21.2x rel. volume Open Argus
Details

Market move: ELAB +3.21% vs previous close. Q3 2026 earnings report

+13.3% Peak in 2 min
$1.60 – $1.70 Day Range
$1.32M Mkt Cap at Last Price

On Nov 16, the day this news came out, the latest delayed price for ELAB is 3.21% above the previous close. Argus tracked a peak move of +13.3% during the session. Our momentum scanner has recorded 18 alerts for this stock so far that day. The latest delayed price is $1.63. Relative volume is exceptionally heavy at 21.2x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Q3 revenue: approximately $2.53 million Gross profit: approximately $601,000 Gross margin: 23.8% +5 more
Q3 revenue
approximately $2.53 million
Q3 2026; up 785% year-over-year and 94% from Q2 2026
Gross profit
approximately $601,000
Q3 2026; up 671% year-over-year and 56% from Q2 2026
Gross margin
23.8%
Q3 2026; down 5.7 percentage points from Q2 2026 and 3.5 points year-over-year
Operating expenses
approximately $3.08 million
Q3 2026; down 27% from Q2 2026
Net loss
approximately $2.24 million
Q3 2026; improved 14% year-over-year and 24% from Q2 2026
Nine-month revenue
approximately $4.52 million
First nine months of 2026
Assets excluding restricted trust cash
approximately $32.7 million
September 30, 2026; up 154% from year-end 2025 and 119% year-over-year
Restricted trust cash
approximately $100.4 million
Held for NSAI public shareholders and unavailable to fund PMGC operations

Key Terms

form 10-q, spac, redeemable noncontrolling interest, non-gaap financial measure
4 terms
form 10-q regulatory
"filed its Quarterly Report on Form 10-Q"
A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.
spac financial
"special purpose acquisition company (“SPAC”)"
A special purpose acquisition company (SPAC) is a company formed specifically to raise money through an initial public offering (IPO) with the goal of buying or merging with an existing private company. For investors, a SPAC offers a way to invest in a potential future business without initially knowing which company it will acquire, making it a way to access new investment opportunities that might otherwise be difficult to invest in directly.
View in glossary
redeemable noncontrolling interest financial
"presented outside of total equity as redeemable noncontrolling interest"
A redeemable noncontrolling interest is a minority ownership stake in a business that the minority owner can require to be bought back for cash or that must be redeemed under set conditions. Investors care because it is not permanent equity: it represents a foreseeable cash obligation and can reduce the parent company’s reported equity and available cash, much like a loan from a roommate you must repay on request rather than shared ownership of the house.
non-gaap financial measure financial
"is a non-GAAP financial measure"
A non-GAAP financial measure is a way companies present their financial results that excludes certain expenses or income to show how they believe their core business is performing. It matters because it can give a clearer picture of how the company is really doing, but it can also be used to make results look better than they actually are.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Fifth consecutive quarter of revenue growth and third consecutive quarter of growth above 90%, as all five of the Company’s acquisitions contribute for a full quarter for the first time
  • Balance sheet now consolidates NorthStrive Acquisition Corp I, PMGC’s first sponsored SPAC, including $100.4 million held in trust; the SPAC has since signed a definitive agreement for a proposed business combination with advanced nuclear technology company Nuclea Energy Inc. at an implied $350 million enterprise value

NEWPORT BEACH, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the “Quarterly Report”) for the three and nine months ended September 30, 2026, with the U.S. Securities and Exchange Commission (“SEC”).

The Quarterly Report is available on the SEC’s website at www.sec.gov under the Company’s filings.

Q3 2026 was the first quarter in which every business PMGC has acquired since July 2025 contributed for a full three months of revenues, and the results reflect the operating base the Company has been assembling. Revenue reached approximately $2.53 million, the highest quarterly revenue in the Company’s history, while operating expenses declined 27% from the second quarter and net loss narrowed for the second consecutive quarter. During the quarter, NorthStrive Acquisition Corp I (Nasdaq: NSAI) (“NSAI”), PMGC’s first sponsored special purpose acquisition company (“SPAC”), completed its $100 million initial public offering and is now consolidated in the Company’s financial statements.

Third Quarter 2026 Financial Highlights

  • Revenue was approximately $2.53 million, up 785% from approximately $286,000 in the third quarter of 2025 and up 94% from approximately $1.31 million in the second quarter of 2026. Q3 2026 revenue alone was more than four times the Company’s revenue for all of 2025.
  • Gross profit was approximately $601,000, up 671% from approximately $78,000 in the third quarter of 2025 and up 56% from approximately $386,000 in the second quarter of 2026, the fifth consecutive quarter of sequential gross profit growth. For the first nine months of 2026, A&B Aerospace, Inc. (“A&B Aerospace”), since its acquisition in May 2026, and Pacific Sun Packaging, Inc. (“Pacific Sun”) generated gross margins of 36.6% and 47.0%, respectively. Consolidated gross margin of 23.8% in the third quarter reflects the former AGA Precision Systems operations, which were merged into A&B Aerospace in July 2026 to share personnel, facilities and equipment and reduce duplicative overhead.
  • Operating expenses were approximately $3.08 million, down 27% from approximately $4.21 million in the second quarter of 2026. Compared to the third quarter of 2025, operating expenses increased 35% while revenue increased 785%.
  • Net loss was approximately $2.24 million, an improvement of 14% from approximately $2.59 million in the third quarter of 2025 and 24% from approximately $2.94 million in the second quarter of 2026. Net loss attributable to PMGC stockholders was approximately $2.41 million in the third quarter of 2026.
  • Nine-month revenue was approximately $4.52 million, approximately 7.7 times the Company’s full-year 2025 revenue of approximately $590,000.

Revenue has grown for five consecutive quarters, in every quarter since the Company completed its first acquisitions in July 2025, driven primarily by the acquisitions of SVM Machining, Inc. (“SVM”) in February 2026 and A&B Aerospace in May 2026:

Quarterly revenueQ2 2025
Q3 2025
Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$nil $285,948 $304,136 $681,994 $1,306,610 $2,530,364 
Sequential growthn/a n/a  6%  124%  92%  94% 

Balance Sheet Highlights as of September 30, 2026

  • Total assets were approximately $133.1 million, compared to approximately $12.87 million at December 31, 2025 and approximately $14.94 million at September 30, 2025. The increase primarily reflects the consolidation of NSAI, including approximately $100.4 million of restricted cash held in NSAI’s trust account (the “Trust Account”), together with the acquisitions of SVM and A&B Aerospace.
  • Excluding restricted cash held in the Trust Account, total assets were approximately $32.7 million, up 154% from year-end 2025 and up 119% year-over-year.
  • Cash, which excludes the Trust Account, was approximately $13.0 million, up 140% from approximately $5.4 million at December 31, 2025 and up 69% from approximately $7.7 million at September 30, 2025.
  • Stockholders’ equity attributable to PMGC was approximately $12.1 million, up 55% from approximately $7.84 million at December 31, 2025 and up 43% compared to September 30, 2025, after a non-cash charge of approximately $4.9 million to additional paid-in capital to remeasure NSAI’s public shares to their redemption value.

Consolidation of NorthStrive Acquisition Corp I

PMGC, through its wholly owned subsidiary NorthStrive Sponsor I LLC, is the sponsor of NSAI, which completed its $100 million initial public offering on August 19, 2026. NSAI is consolidated in PMGC’s financial statements beginning in the third quarter of 2026. The approximately $100.4 million in the Trust Account is held for the benefit of NSAI’s public shareholders and is restricted cash that is not available to fund PMGC’s operations, and an equal amount is presented outside of total equity as redeemable noncontrolling interest. Third quarter interest income of approximately $489,000 included approximately $423,000 earned on the Trust Account. The underwriters’ over-allotment option in NSAI’s initial public offering expired unexercised on October 1, 2026.

Operational Highlights

  • Aerospace platform consolidated under A&B Aerospace. On July 2, 2026, AGA Precision Systems LLC merged into A&B Aerospace, consolidating PMGC’s aerospace precision manufacturing under one company to share personnel, equipment, certifications and administrative support. A&B Aerospace, founded in 1948 and AS9100D certified, serves long-standing Tier 1 customers including Boeing, Honeywell and Moog, and contributed approximately $2.13 million of revenue at a 36.6% gross margin from its acquisition on May 11, 2026 through September 30, 2026.
  • Long-term agreement with PAD Group. A&B Aerospace entered into a long-term agreement with Precision Aerospace & Defense Group, Inc. (“PAD Group”), effective July 23, 2026, to manufacture precision-machined aerospace and defense components under purchase orders, including orders associated with U.S. federal government prime contracts. The agreement has a two-year term with automatic one-year renewals and no guaranteed minimum purchase volume.
  • Investment in automation and lights-out manufacturing. In August 2026, the Company announced that it has invested in advanced manufacturing equipment for its aerospace and defense manufacturing businesses, including a 5-axis machining center, a CNC lathe with Y-axis and live tooling and a Swiss-type CNC lathe with bar feeder that enables lights-out manufacturing, and that it is evaluating robotics and automation technologies to increase capacity and efficiency.
  • Specialty IT packaging. Pacific Sun, which supplies protective packaging for semiconductor, data center and networking hardware to more than 300 commercial customers, generated a gross margin of 47.0% in the first nine months of 2026, up from 29.1% for the period from its acquisition in July 2025 through year-end 2025, which PMGC believes reflects improved unit economics under its ownership.
  • Defense technology. NorthStrive Defense Tech LLC executed a definitive exclusive, worldwide license with the Florida State University Research Foundation for U.S. Patent No. 12,291,334, a multi-domain drone payload technology for aerospace and defense applications and engaged Deploy360 to independently validate the patented GPS-denied drone navigation technology it holds under option.
  • Biosciences. NorthStrive Biosciences Inc. (“NorthStrive Biosciences”) reported positive results from Phase III of its AI-driven drug discovery program with Yuva Biosciences, in which four AI-selected candidates increased ANT1 protein expression in primary human skeletal muscle cells, and announced an expansion program to advance the four compounds toward lead and backup nomination for potential cardiac disease and obesity applications. It also announced two U.S. patent applications covering EL-22 and EL-32 for muscle loss in microgravity and a statement of work with Charles River Laboratories supporting both programs.
  • Royalty stream. In September 2026, the Company announced a payment agreement with Longevity Health Holdings under which the acknowledged 2025 royalty of $94,937 and future royalties from a business the Company divested in January 2025 are payable to NorthStrive Biosciences in monthly installments of $10,000 beginning October 15, 2026.

Recent Developments Subsequent to Quarter-End

  • Proposed NSAI business combination with Nuclea Energy. On October 30, 2026, NSAI entered into a definitive business combination agreement with Nuclea Energy Inc. (“Nuclea”), a development-stage company developing advanced nuclear technologies including the Morpheus Micro Modular Reactor, which was announced on November 2, 2026. The agreement provides for share consideration based on a $350 million value for Nuclea, subject to adjustments at closing, plus up to 15,000,000 earnout shares subject to the achievement of specified milestones. The proposed transaction is expected to close in the first half of 2027, and the agreement may be terminated if closing has not occurred by April 30, 2027. Closing is subject to conditions that include NSAI and Nuclea shareholder approvals, an effective registration statement on Form S-4, a receipt for a final Canadian prospectus, Nasdaq listing approval, completion of Nuclea’s pending acquisition of the Moltex assets by November 30, 2026, and NSAI having available cash of at least $3.0 million at closing. PMGC, an existing investor in Nuclea, has agreed to subscribe for $1,845,000 principal amount of debentures issued by a Nuclea subsidiary to fund the Moltex acquisition. NSAI has disclosed substantial doubt about its ability to continue as a going concern if it does not complete a business combination by August 19, 2027. There can be no assurance that the proposed transaction will be completed.
  • EL-32 preclinical results. On November 5, 2026, the Company announced the completion of NorthStrive Biosciences’ preclinical proof-of-concept study of EL-32 in combination with semaglutide, which generated the first controlled in vivo data on EL-32 in a GLP-1 combination setting. The study identified a statistically significant greater absolute lean mass at the highest tested EL-32 dose in combination with semaglutide compared with semaglutide alone. The finding is preliminary and limited to specific measures and doses; the combination did not demonstrate a consistent additive metabolic benefit over semaglutide alone, and EL-32 alone did not demonstrate meaningful improvements. The contract research organization noted that the semaglutide dose used left a limited window to detect an additional effect of EL-32, and NorthStrive Biosciences plans to design a follow-on preclinical study using a lower dose of semaglutide, with lean mass and body composition as the primary endpoints.
  • Investment in Orbit2Orbit. Following the non-binding term sheet announced in August 2026, PMGC Capital LLC completed a subscription for common shares of Orbit2Orbit Pty Ltd, an Australian space technology company developing in-space logistics and infrastructure, as announced on November 10, 2026.

In the first nine months of 2026, PMGC generated approximately $4.52 million of revenue, approximately 7.7 times its revenue for all of 2025, and quarterly revenue has grown from approximately $286,000 to approximately $2.53 million for the three-month periods ended September 30, 2025 and 2026, respectively. Since July 2025, the Company has completed five acquisitions and built an operating base with exposure to industries that PMGC believes are supported by strong, long-term demand: aerospace, defense and space; medical and semiconductor manufacturing; and the data center and AI infrastructure supply chain. Alongside that operating base, PMGC is advancing defense technology and biosciences development programs and has launched a SPAC sponsorship platform. The Company plans to continue investing in the capacity and automation of its existing businesses and to pursue additional acquisitions of established, cash-flow-positive businesses, and believes it is still early in building the scale of its platform.

Selected Financial Information (Unaudited, in U.S. Dollars)

Results of operations, three months ended

 September 30, 2026June 30, 2026September 30, 2025Change vs. Q2 2026Change vs. Q3 2025
Revenue2,530,364 1,306,610 285,948 94%
785%
Gross profit601,444 385,691 78,030 56%
671%
Gross margin23.8% 29.5% 27.3% (5.7) pts
(3.5) pts
Total operating expenses3,080,365 4,212,900 2,276,931 (27)%
35%
Net loss from continuing operations(2,220,853)(2,958,972)(2,616,018)Narrowed 25%Narrowed 15%
Net loss(2,242,738)(2,941,382)(2,594,320)Narrowed 24%Narrowed 14%
Net loss attributable to PMGC stockholders(2,406,301)(2,941,382)(2,594,320)Narrowed 18%Narrowed 7%

Selected balance sheet data

 September 30, 2026June 30, 2026December 31, 2025September 30, 2025
Cash12,981,851 18,141,7585,402,3337,700,562
Restricted cash held in Trust Account100,422,693 n/an/an/a
Total assets133,101,280 36,564,49612,868,47314,938,018
Less: restricted cash held in Trust Account(100,422,693)n/an/an/a
Total assets excluding restricted cash held in Trust Account (1)32,678,587 36,564,49612,868,47314,938,018
Total liabilities21,033,639 19,827,5975,031,1116,447,363
Redeemable noncontrolling interest100,422,693 n/an/an/a
Total PMGC Holdings Inc. stockholders’ equity12,109,044 16,736,8997,837,3628,490,655

(1) Total assets excluding restricted cash held in the Trust Account is a non-GAAP financial measure. The Company presents it because the Trust Account is not available to fund PMGC’s operations and its inclusion affects comparability with prior periods. The table above reconciles this measure to total assets, the most directly comparable measure under U.S. generally accepted accounting principles (“GAAP”). This measure should be considered in addition to, and not as a substitute for, total assets presented in accordance with GAAP.

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. 

Additional Information and Where to Find It

In connection with the proposed business combination between NSAI and Nuclea, NSAI intends to file relevant materials with the SEC, including a registration statement on Form S-4, which will include a proxy statement/prospectus of NSAI. Investors and shareholders of NSAI are urged to read the registration statement and the proxy statement/prospectus, when they become available, and any other relevant documents filed with the SEC, because they will contain important information about the proposed transaction. The documents filed by NSAI with the SEC may be obtained free of charge on the SEC’s website at www.sec.gov. NSAI is a separate SEC registrant.

No Offer or Solicitation

This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities of PMGC or NSAI, or a proxy statement or the solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact: IR@pmgcholdings.com 


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were PMGC Holdings’ Q3 2026 revenue and net loss?

PMGC reported approximately $2.53 million in revenue and a net loss of approximately $2.24 million for the quarter ended September 30, 2026. Revenue increased 785% year over year and 94% sequentially. Net loss narrowed 14% year over year and 24% sequentially.

Can PMGC use NorthStrive Acquisition Corp I’s trust cash for operations?

No. Approximately $100.4 million in NSAI’s trust account is restricted, held for NSAI public shareholders and unavailable to fund PMGC operations. An equal amount is presented outside total equity as redeemable noncontrolling interest. PMGC consolidates NSAI in its financial statements beginning in the third quarter of 2026.

What conditions and deadlines apply to the NSAI and Nuclea Energy merger?

Closing requires NSAI and Nuclea shareholder approvals, an effective Form S-4, a final Canadian prospectus receipt, Nasdaq listing approval, Nuclea’s Moltex acquisition completion by November 30, 2026, and at least $3.0 million in available NSAI cash. Closing is expected in the first half of 2027; the agreement permits termination if closing has not occurred by April 30, 2027.

What additional consideration could Nuclea receive in the NSAI transaction?

The agreement provides for up to 15,000,000 earnout shares, subject to specified milestones. These are in addition to share consideration based on a $350 million value for Nuclea, subject to adjustments at closing.

Keep reading